Regeneron says that a combination of Eylea and nesvacumab being co-developed with Bayer will not move into Phase III testing for two eye conditions following disappointing Phase II data. More: Regeneron calls time on Eylea/nesvacumab combo Source: News
read moreCost regulators for NHS treatments in England and Wales have rejected funding for Eisai’s Halaven as a second-line of attack against a certain form of breast cancer. More: NICE turns down earlier use of Eisai’s Halaven Source: News
read moreViiV Healthcare has kicked off a late-stage study testing a long-acting, two-drug regimen of its cabotegravir and Janssen’s rilpivirine in virally suppressed adults with HIV-1 infection More: ViiV trials long-acting, two-drug HIV regimen Source: News
read moreAstraZeneca has entered into a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China. More: AZ forms new company in China Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals